Vyndaqel 20 mg, Weichkapseln

7680670830010 CH-67083 Weichkapseln
Vyndaqel 20 mg, Weichkapseln
Vyndaqel 20 mg, Weichkapseln
Vyndaqel 20 mg, Weichkapseln
1 / 3
google

Article details

Package size
30
Selling units
30
Measure
Kapsel(n)
Galenic form
Weichkapseln
Galenic group
Tabletten

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Patient information leaflet
Allemand
16/04/2025
Patient information leaflet
Français
16/04/2025
Patient information leaflet
Italien
16/04/2025
Summary of Product Characteristics
Allemand
16/04/2025
Summary of Product Characteristics
Français
16/04/2025
Summary of Product Characteristics
Italien
16/04/2025

Detailed composition

Substance Quantity Type Category
(N/A)
20.0 MG Substance WIZUS
(N/A)
12.2 MG Substance Wirkstoff (Principe actif)
(N/A)
- Substance Hilfsstoff ohne Deklarationspflicht (Excipient sans obligation de déclaration)
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HNIDK
(N/A)
- Substance HBESI
(N/A)
- Substance FTODK
(N/A)
- Substance FNIDK
(N/A)
- Substance Hilfsstoff ohne Deklarationspflicht (Excipient sans obligation de déclaration)
(N/A)
- Substance Hilfsstoff ohne Deklarationspflicht (Excipient sans obligation de déclaration)
(N/A)
- Substance HNIDK
(N/A)
- Substance FIMDK
(N/A)
- Substance FIMDK

Authorization holder

Pfizer AG

8052 Zürich

Authorization information

Swissmedic authorization number
67083
Drug name
Vyndaqel 20 mg, Weichkapseln
Galenic form
KAPWE
ATC Code
N07XX08
Authorization status
Z
Dispensing category
B
First authorization
05/03/2020
Authorization expiration date
31/12/9999
IT Number
01.99.0.
Domain
Human medicine
Field of application
Behandlung der Transthyretin-Amyloidose bei erwachsenen Patienten mit Wildtyp- oder hereditärer Kardiomyopathie

Package details

Description (FR)
VYNDAQEL caps moll 20 mg 30 pce
Description (DE)
VYNDAQEL Weichkaps 20 mg 30 Stk
Market launch
05/03/2020
Narcotic (BTM)
No